EP0901536A1 - Dispositif d'insonorisation pour voies ferrees - Google Patents

Dispositif d'insonorisation pour voies ferrees

Info

Publication number
EP0901536A1
EP0901536A1 EP97922748A EP97922748A EP0901536A1 EP 0901536 A1 EP0901536 A1 EP 0901536A1 EP 97922748 A EP97922748 A EP 97922748A EP 97922748 A EP97922748 A EP 97922748A EP 0901536 A1 EP0901536 A1 EP 0901536A1
Authority
EP
European Patent Office
Prior art keywords
plate
plates
partial
soundproofing device
support sections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP97922748A
Other languages
German (de)
English (en)
Other versions
EP0901536B1 (fr
Inventor
Bernhard Neumann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gmundner Fertigteile GmbH and Co KG
Original Assignee
Gmundner Fertigteile GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT93496A external-priority patent/AT403809B/de
Priority claimed from AT0101596A external-priority patent/AT405426B/de
Application filed by Gmundner Fertigteile GmbH and Co KG filed Critical Gmundner Fertigteile GmbH and Co KG
Priority to SI9730491T priority Critical patent/SI0901536T1/xx
Publication of EP0901536A1 publication Critical patent/EP0901536A1/fr
Application granted granted Critical
Publication of EP0901536B1 publication Critical patent/EP0901536B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01B—PERMANENT WAY; PERMANENT-WAY TOOLS; MACHINES FOR MAKING RAILWAYS OF ALL KINDS
    • E01B19/00—Protection of permanent way against development of dust or against the effect of wind, sun, frost, or corrosion; Means to reduce development of noise
    • E01B19/003—Means for reducing the development or propagation of noise

Definitions

  • the invention relates to a soundproofing device for tracks, with sound-absorbing plates mounted on the rails of the track, which are supported on the rails by elastic profiles, the plates arranged between the rails cantilevering the space between the rails. Furthermore, the invention relates to sound-absorbing panels for such a soundproofing device.
  • the plates arranged between the rails of the track consist of three layers or layers which are supported by elastic profiles on the rail foot, web and on the underside.
  • the upper layer consists of steel wire fabric that can be walked on, the edge of which is glued, welded or vulcanized into the profile.
  • the middle layer is designed as a sound absorption layer and consists of glass wool or rock wool. This sound absorption layer lies on the lower layer, which is designed as a perforated wall or grate and is supported in a recess in the profile in the region of the rail foot.
  • the panels are also arranged on the outside of the rail and angled upward at the ends in order to form a lateral soundproofing wall.
  • Such mineral wool panels have adequate sound absorption at high frequencies, but have inadequate sound absorption at low frequencies.
  • a further disadvantage of this construction is that the walkable perforated wall made of steel wire mesh can detach itself from its anchoring in the profiles at higher and repeated loads, so that the sound absorption layer underneath can be damaged.
  • the dust penetrating through the perforated wall can be deposited on the upper side of the sound absorption layer and thus the sound damping effect can deteriorate increasingly.
  • the invention has for its object to provide a soundproofing device for tracks with sound-absorbing plates, which has good sound absorption or damping over the entire frequency range essential for the sound level of rail traffic, with a permanent mechanical Strength of the device should be guaranteed.
  • the soundproofing device of the type mentioned at the outset in that the plates consist of particles of porous lightweight construction material which are joined together with a binder, and in that the plates have embedded reinforcement and are arranged uncovered.
  • the airborne noise emanating in particular from the wheels of a rail vehicle and from the rails is absorbed on the surface of the plates by the pores of the particles and can also be selected if a structure is left that leaves fine spaces between the particles, via spaces or channels between the particles penetrate deeper into the plate to gradually be completely dampened there.
  • the reinforcement of the panels also ensures that they can be walked on.
  • the top of the plates is structured, and even better results can be achieved if the structuring is irregular.
  • the top of the plates is preferably provided with ribs running parallel to the rails, which results in structuring that is simple to construct.
  • the ribs have a trapezoidal cross-section, since this makes it easier to absorb obliquely incident sound waves.
  • the wall of the cavity resonators and their sound openings are provided with a sound-absorbing structure, and / or if the wall of the cavity resonators and their tubular sound openings are provided with a sound-absorbing layer are provided.
  • the cavities forming the cavity resonators are designed to be open at the bottom and are covered with a lower plate.
  • the cavities forming the cavity resonators are designed to be open at the bottom and form a resonance cavity together with the track bedding.
  • the damped resonance frequency of the cavity resonators is within a frequency range from 150 to 1000 Hz, preferably between 500 and 1000 Hz.
  • a special embodiment is also provided in which the installation and removal of the plates to be provided between the two rails of a track can be accomplished in a very simple manner.
  • This embodiment of the soundproofing device is characterized in that the space lying between the two rails of a track is bridged with partial plates arranged in pairs, each of which engages with at least one supporting rib in the link chambers of the rails, the partial plates of each pair of plates at their mutually facing edges are supported on one another and in this case support sections and support sections are provided alternately in a meandering manner on each section plate along the edge facing the other section plate, the support sections being formed by depressions extending from the top of the plate and facing the other section plate and under the support sections from the underside of the plate, upward depressions are formed, which are complementary to the depressions of the support sections, and the support sections of a partial plate on the support sections the other partial plate and the support sections of the other partial plate rest on the supporting sections of the one partial plate.
  • the zones of the partial plates of each pair of plates to be joined in an articulated manner can simply be plugged together when the partial plates are unfolded, after which the partial plates can be inserted between the rails without problems by leveling the pair of plates, and the partial plates also become Loads not pushed apart.
  • a preferred type of the last-mentioned embodiment which is characterized in that projections and recesses shaped complementarily to the projections, into which the projections engage, are provided on those surfaces on which the partial plates of a pair of plates abut one another, for mutual locking of the partial plates, offers the advantage that the cohesion of the partial plates of a pair of plates is ensured even over very long periods of time even when unfavorable vibrations act on the partial plates.
  • Such a crowning can be formed on a partial plate by a surface section which extends from the edge facing the other partial plate of the pair of plates and extends away from the underside of the plate, and a subsequent surface section which approaches the underside of the plate. If one wishes to additionally provide a latching in such a configuration of the partial plates, it is advantageous if they are designed in such a way that projections pointing downward are provided on the end edges of the supporting sections and recesses complementary to these projections are provided on the supporting surfaces of the supporting sections.
  • An embodiment which is particularly favorable for the course of the leveling process when installing the partial plates and for achieving the most stable possible position of the two partial plates of a pair of plates relative to one another in the installed state characterized in that the cambered shaped wings are shaped according to a toothing which, up to the leveled position of the partial plates of the respective pair of plates, enables sliding or rolling movement of the facing wings and supporting surfaces towards one another and in the leveled position of these partial plates against one another Movement of these partial plates to each other blocks.
  • the reinforcement provided in the sub-panels extends over the panel surface and engages in the supporting sections and in the supporting sections and in the supporting ribs. It is also advantageous if one provides that an elastic or / or shock-absorbing insert or coating is provided between the wings provided on the support sections and the support surfaces provided on the support sections.
  • a sound-absorbing plate according to the invention is characterized in that the plate consists of particles made of porous lightweight material, which are joined together with a binder, that the plate has an embedded reinforcement, and that in the plate cavity resonators with a large area of the Plate directed tubular sound openings are formed, which large area to form the top is provided when installing the plate in the track. It is advantageous here if the cavities forming the cavity resonators are designed to be open and widening towards the large area that lies on the side of the plate facing away from the tubular sound openings. A further development is characterized in that the cavities forming the cavity resonators are covered with a lower plate on the side facing away from the tubular sound openings.
  • Embodiments of a plate designed according to the invention which are provided for the aforementioned formation with partial plates to be joined to form a pair of plates, are characterized in that the plate consists of particles of porous lightweight building material, which are joined together with a binder, so that the plate is an embedded one Reinforcement has that the plate is provided on one edge side with a support rib for engaging in the tab chambers of rails and on the edge side opposite this support rib has meandering succession of support sections and support sections, the support sections extending from the top of the plate and depressions extending to the edge are formed and under the support sections, from the underside of the plate, upward depressions are formed, which are complementary to the depressions of the support sections.
  • cavity resonators are formed in the plate with tubular sound openings directed towards a large area of the plate, which large area is provided for forming the upper side when the plate is installed in the track. It is also advantageous here if the reinforcement provided in the plate extends over the entire surface of the plate and extends into the support sections and into the support sections and into the support rib. If desired, the plates or partial plates can also be provided with a frame running along the edge, preferably consisting of metal or fiber-reinforced plastic.
  • FIG. 1 shows a plan view of a track with sound-absorbing plates arranged between the rails
  • FIG. 2 shows a section along the line II-II in Fig.l
  • 3 shows an embodiment of a plate in cross section
  • FIG. 4 shows an enlarged detail of the surface of the plate according to FIG. 2 or 3;
  • FIG. 5 shows an embodiment of a soundproofing device designed according to the invention with partial plates in a top view
  • FIG. 10 shows a variant with regard to the design of the support sections and the support sections in a sectional representation corresponding to FIG. 7,
  • FIG. 11 shows another embodiment of a soundproofing device designed according to the invention with partial panels, in a top view
  • FIG. 16 shows a variant with regard to the design of the support sections and the support sections of the partial plates in a sectional representation corresponding to FIG. 13.
  • sound-absorbing plates 3 are arranged next to one another in the longitudinal direction of the track between the rails 2.
  • the generally rectangular plates 3 have, on their two edges along the rails 2, projecting support ribs 4, which are interposed with elastic profiles 5, for example made of rubber or elastomer, support on the rail base 6, on the rail web 7 and on the underside of the rail head 8 of the rails 2.
  • the plates 3, the surface of which is shown enlarged in FIG. 4, consist of particles 9 made of porous lightweight material, which are joined together with a suitable binder.
  • Plastic granulate, granular or spherical and fired alumina particles, granular slag particles, or similar fired natural or artificially produced materials are used as the lightweight construction material, these particles being selectively connected with a suitable plastic binder or cement, so that small spaces or channels 10 remain, which allow air ducting and drainage of penetrating rain or melt water.
  • the panels 3 are provided with a reinforcement 11, for example made of steel or other metals, fiber-reinforced plastic, glass fiber mats or the like.
  • the surface of the plates 3 can be increased by structuring.
  • the top 12 of the plates 3 can be provided with ribs 13 which run parallel to the rails 2 and are spaced apart from one another and which, as shown in FIG. 3, have a trapezoidal cross section and a height a above the rail head 8 which are closed ⁇ not exceeding 5 cm.
  • the structure can also be irregular, for example by increasing or decreasing the spacing of the ribs 13 from one another.
  • a structuring of the top 12 for example, truncated cones, truncated pyramids, cylinders, cuboids, etc. can also be provided, which are arranged either at the same or at different distances from one another.
  • 3 cavity resonators 14 in the manner of the Helmholz resonator are formed in the plates, the tubular sound openings of which 15 are provided on the top 12 of the plates 3.
  • the cavities forming the cavity resonators 14 are frustoconical and open at the bottom, the openings formed thereby being covered by a sub-plate 16, for example glued to the plate 3, in order to form the cavity resonator 14 .
  • the cavities forming the cavity resonators 14 can also be designed to deviate from the shape of a truncated cone, for example spherical, cylindrical, pyramid-shaped, etc., in order to achieve a different frequency behavior in the case of sound absorption.
  • the volumes of the cavity resonators 14 and the dimensions of the tubular sound openings can be varied in order to achieve the desired frequency behavior or frequency absorption spectrum. As shown in FIG.
  • the tubular sound openings 15 open perpendicular to the top 12 of the plate 3.
  • the tubular sound openings 15 can also open at an angle to the top 12 of the plates 3 in order to be able to better absorb obliquely incident sound waves .
  • the plates 3 with the cavity resonators 14 can be produced in a rectangular shape in which positive shapes of the cavity resonators with attached pipe pieces for the sound openings are used, whereupon the mold is filled with the particles 9 and a binder and demolded after the binder has hardened becomes.
  • Prefabricated cavity resonators with attached pipe pieces as sound openings can also be used as positive forms, which either consist of a suitable sound-absorbing material or are provided on the inside with a layer of sound-absorbing material.
  • sound-absorbing plates with cavity resonators can also be provided on the outside of the rails 2.
  • the plate 18 shown in dash-dotted lines on the right rail 2 is at one End, similar to the plate 3 lying between rails 2, is supported on the rail 2 via an elastic profile 5 and at the other end via an elastic strip 19 and fixed by means of a fastening element, in particular a screw 20.
  • the plate 21 on the left rail 2, also shown with a dash-dotted line, is supported and fixed in the same way as the plate 18, but has an end region that is angled upwards on the outside in order to form a soundproofing wall.
  • the two plates 18, 21 likewise have reinforcement (not shown) and, if appropriate, a structure in the form of ribs (not shown). If desired, the plates can also be provided with a frame running along the edge.
  • the space 22 lying between the two rails 2 of a track 1 is filled or bridged with paired sound-absorbing partial plates 3a, 3b.
  • These sub-plates 3a, 3b have support ribs 4 which engage in the tab chambers 23 of the rails 2, and elastic profiles 5 with an approximately C-shaped cross section are inserted between the support ribs 4 and the rails 2.
  • the partial plates 3a, 3b are supported with their supporting ribs 4 on the rail foot 6 and laterally against the rail web 7 and held upwards by engagement under the rail head 8.
  • the partial plates 3a, 3b bridge the distance 24 between the rails 2 in a self-supporting manner.
  • a plurality of support ribs 4 are provided on each of the partial plates 3a, 3b, which are arranged at a distance from one another in order to leave the fastening elements 25 provided for the rails 2 accessible.
  • each pair of plates are supported on one another, so that each pair of plates forms an assembled body which bridges the distance 24 between the rails 2 in a self-supporting manner.
  • the support sections 28 being formed by depressions 30 which extend from the top side 12 of the plate and extend to the edge facing the other partial plate; under the support sections 29, starting from the lower side 31 of the plate, upward depressions 32 are formed, and the support sections of the partial plate 3a lie on the supporting sections of the partial plate 3b and the supporting sections of the partial plate 3b rest on the supporting sections of the partial plate 3a;
  • the depressions 30 are complementary to the depressions 32, so that the support surfaces 34 formed on the support sections 29 by the depressions 32 lie substantially snugly on the support surfaces 33 formed by the depressions 30 on the support sections 28.
  • the partial plates 3a, 3b In order to insert the partial plates 3a, 3b in pairs between the rails 2 of a track, they can first be arranged in the unfolded position, as shown in FIG. 9, and in the process they can be inserted into one another with their meandering edges 26, 27 also arranges the elastic profiles 5, which have a C-shaped cross section, between the supporting ribs 4 of the partial plates 3a, 3b and the rails 2. Then the partial plates 3a, 3b are pivoted or folded down, as indicated by the arrow 35, until they assume the leveled position shown in FIGS. 5 to 7, in which the partial plates 3a, 3b of each pair of plates space 22 between bridge the rails 2 in a self-supporting manner.
  • the support surfaces 33 provided in the support sections 28 have a cambered shape, and there is such a cambered shape also in the support surfaces 34 provided on the support sections 29, and this cambered shape of the named surfaces ensures that the partial plates retain their shape 3a, 3b create ge, which in the leveled position of the partial plates 3a, 3b inhibits a mutual movement of these partial plates in the direction of the plate plane (arrows 36).
  • projections 37 are provided on the support surfaces 34 and recesses 38 are provided on the support surfaces 33, which are complementary to the projections 37; in the leveled position of the partial plates, the Projections 37 into the recesses 38, so that there is a mutual locking of the partial plates 3a, 3b.
  • an elastic and / or shock-absorbing insert or coating can be provided between the support surfaces 33 and the support surfaces 34.
  • the supporting surfaces 33 provided on the supporting sections run, starting from the edge 26 or 27 of the respective partial plate 3a or 3b, first rising steeply from the underside 31 of the plate and then becoming flatter, which is advantageous for joining the partial plates to the pairs of plates. From a geometrical point of view, it is favorable if such domed wings are shaped according to a toothing which, up to the leveled position of the partial plates 3a, 3b of the respective plate pair, enables a sliding movement or rolling movement of the mutually facing wings and supporting surfaces on one another, and in the leveled position (Fig. 5 to 7) locks these partial plates against movement to each other.
  • This geometrical shape corresponding to a toothing can extend up to the top 12 of the plate.
  • the projections 37 can, as shown in FIGS. 5 to 8, be provided on the end edges 39 of the support sections 29, which can bring advantages when joining the partial plates, but it is also possible to place such projections 37 elsewhere, e.g. slightly removed from the edge of the support surfaces.
  • the support surfaces 33 and the support surfaces 34 are largely flat; In this case, too, recesses 38, into which projections 37 engage, are provided for mutual locking of the partial plates 3a, 3b.
  • the two partial plates 3a, 3b of a pair of plates lie on one another in a meandering manner on the underside 31 of the plate, so that the mutually facing edges of the partial plates 3a , 3b run on the underside of the plate following a meandering line 43. This results in a very intimate cohesion of the partial plates 3a, 3b forming a pair of plates.
  • the partial plates 3a, 3b are rounded at the mutually facing edges 26, 27 from the underside 31 of the plate upwards, the radius of curvature of this rounding being equal to or smaller than the distance 41 between the edges 26, 27 and the rail-side edges 42 of the partial plates 3a, 3b. This measure is also advantageous for an unrestrained process of inserting the partial plates.
  • the reinforcement 11 provided in the partial plates extends over the entire surface extent of the partial plates 3a, 3b and, as indicated by the broken lines in FIG. 8, both in the support sections 28 and in the support sections 29 as well engages in the support ribs 4.
  • cavity resonators 14 with sound openings 15 can be provided, as is the case e.g. 11 to 14 is shown.
  • the plates can also be provided with frames 44, as is e.g. is indicated by dashed lines in FIG.

Landscapes

  • Engineering & Computer Science (AREA)
  • Architecture (AREA)
  • Civil Engineering (AREA)
  • Structural Engineering (AREA)
  • Building Environments (AREA)
  • Soundproofing, Sound Blocking, And Sound Damping (AREA)
  • Railway Tracks (AREA)
  • Power-Operated Mechanisms For Wings (AREA)
  • Devices Affording Protection Of Roads Or Walls For Sound Insulation (AREA)
  • Signal Processing Not Specific To The Method Of Recording And Reproducing (AREA)
  • Noise Elimination (AREA)
  • Magnetic Heads (AREA)
  • Holo Graphy (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Bridges Or Land Bridges (AREA)

Abstract

L'invention concerne un dispositif d'insonorisation de voies ferrées (1), comportant des plaques (3) à absorption acoustique montées au niveau des rails (2) de la voie ferrée (1), qui s'appuient sur les rails par l'intermédiaire de profilés (5) élastiques et recouvrent de manière non soutenue l'espace entre les rails (2). Pour améliorer l'insonorisation des plaques (3), il est prévu que lesdites plaques (3) se composent de particules (9) en matériau poreux pour construction légère, agglomérées avec un liant. Les plaques (3) présentent une armature (11) encastrée. Avantageusement, il est également prévu dans les plaques (3), des cavités résonnantes (14) amortissant le bruit. Dans un mode particulier de réalisation, il est prévu que l'espace entre les rails (2) d'une voie soit recouvert de plaques partielles (3a, 3b) appariées, qui s'appuient mutuellement les unes sur les autres au niveau de leurs bords adjacents.
EP97922748A 1996-05-29 1997-05-23 Dispositif d'insonorisation pour voies ferrees Expired - Lifetime EP0901536B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI9730491T SI0901536T1 (en) 1996-05-29 1997-05-23 Track soundproofing arrangement

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AT93496A AT403809B (de) 1996-05-29 1996-05-29 Schallschutzeinrichtung für gleise
AT93496 1996-05-29
AT934/96 1996-06-11
AT1015/96 1996-06-11
AT101596 1996-06-11
AT0101596A AT405426B (de) 1996-06-11 1996-06-11 Schienengleiche eindeckung für gleise
PCT/AT1997/000109 WO1997045592A1 (fr) 1996-05-29 1997-05-23 Dispositif d'insonorisation pour voies ferrees

Publications (2)

Publication Number Publication Date
EP0901536A1 true EP0901536A1 (fr) 1999-03-17
EP0901536B1 EP0901536B1 (fr) 2002-12-11

Family

ID=25594370

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97922748A Expired - Lifetime EP0901536B1 (fr) 1996-05-29 1997-05-23 Dispositif d'insonorisation pour voies ferrees

Country Status (14)

Country Link
US (1) US6253872B1 (fr)
EP (1) EP0901536B1 (fr)
JP (1) JP3822641B2 (fr)
CN (1) CN100424268C (fr)
AT (1) ATE229595T1 (fr)
AU (1) AU738889B2 (fr)
CA (1) CA2255946C (fr)
DE (1) DE59708955D1 (fr)
DK (1) DK0901536T3 (fr)
ES (1) ES2186891T3 (fr)
HU (1) HU221872B1 (fr)
NO (1) NO316078B1 (fr)
TW (1) TW345603B (fr)
WO (1) WO1997045592A1 (fr)

Families Citing this family (311)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19812481C2 (de) * 1998-03-21 2002-08-22 Johann Rath Vorrichtung zur Dämpfung von Schallemissionen an Gleisanlagen
DE29905550U1 (de) * 1999-03-26 2000-08-24 DVG Deutsche Verpackungsmittel GmbH, 90552 Röthenbach Absorptionsbelag zur Reduzierung der Schallabstrahlung für Gleiskörper
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US6481637B1 (en) * 2000-11-20 2002-11-19 Mcqueen Philip Jeffrey Rail pad and method for strain attentuation
DE10111919A1 (de) * 2001-03-13 2002-09-19 Boegl Max Bauunternehmung Gmbh Fahrwegträger
HU224236B1 (hu) * 2001-12-14 2005-06-28 Attila Szebeni Vasúti acélhidaknál alkalmazható, egymáshoz csatlakoztatott elemekbõl álló, zaj- és rezgéscsökkentett mûanyag járólemezrendszer
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (fr) 2002-07-02 2004-01-15 Health Research, Inc. Synthese efficace de pyropheophorbide a et ses derives
AT6414U1 (de) * 2002-07-17 2003-10-27 Gmundner Fertigteile Gmbh Gleisabdeckung
GB2399123B (en) * 2003-03-05 2006-03-01 Corus Uk Ltd Rail damper
WO2004099162A1 (fr) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Antagoniste de proteine bcl-2 a base de diazodioxyde polycyclique
US20040242886A1 (en) * 2003-04-30 2004-12-02 Sandeep Gupta Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
EP1628666B1 (fr) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Composes et leurs utilisations pour la modulation de l'amyloide-beta
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
WO2005090370A1 (fr) 2004-02-05 2005-09-29 The Regents Of The University Of California Agents pharmacologiquement actifs contenant des phosphonates esterifies, et leurs procedes d'utilisation
US20100126797A1 (en) * 2004-02-12 2010-05-27 Humphries Eric C Panel Assembly For Traffic Noise Barrier Wall
US8616331B2 (en) 2004-02-12 2013-12-31 Eric C. Humphries Panel assembly for traffic noise barrier wall
US7546900B2 (en) * 2004-02-12 2009-06-16 Evonik Cyro Llc Panel assembly for traffic noise barrier wall
TWI347390B (en) * 2004-03-05 2011-08-21 Gmundner Fertigteile Gmbh Noise-reducing track cover
JP2007538103A (ja) 2004-05-20 2007-12-27 ザ スクリップス リサーチ インスティテュート トランスサイレチン安定化
NZ588432A (en) 2004-09-17 2012-03-30 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
US20060067889A1 (en) * 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
US20070131480A1 (en) * 2004-12-06 2007-06-14 Corbin Maxwell H Jr Sound arresting barrier
US7464791B2 (en) * 2005-01-27 2008-12-16 Pretty Products, Llc Acoustic mats and methods for making the same
US20060230699A1 (en) * 2005-03-22 2006-10-19 Keene James R Sound control flooring systems and methods therefor
EP1866319B1 (fr) 2005-04-01 2011-11-23 The Regents of The University of California Nucleosides phosphono-pent-2-en-1-yle et analogues
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
WO2007106537A2 (fr) * 2006-03-13 2007-09-20 Activx Biosciences, Inc. Aminoquinolones utilisées comme inhibiteurs de la gsk-3
EP2007373A4 (fr) * 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc Inhibition de la toxicité de l'alpha-synucléine
AU2007260579B2 (en) * 2006-06-13 2012-09-06 Newstyle Nominees Pty Ltd Rail track crossing
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
CN101535304A (zh) 2006-09-21 2009-09-16 埃迪威克斯生物科学公司 丝氨酸水解酶抑制剂
BRPI0715579A2 (pt) 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
JP5013590B2 (ja) * 2006-11-14 2012-08-29 エンデバーハウス株式会社 伸縮性に優れた線路用吸音材
US20080146605A1 (en) 2006-12-19 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
WO2008079371A1 (fr) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulateurs du récepteur du c3a et leurs procédés d'utilisation
WO2008106167A1 (fr) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Polythérapie incluant des inhibiteurs de métalloprotéinases matricielles et des inhibiteurs de caspases pour le traitement de maladies hépatiques
BRPI0808089A2 (pt) 2007-02-28 2014-07-15 Conatus Pharmaceuticals Inc Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
ES2693948T3 (es) 2007-03-15 2018-12-14 Auspex Pharmaceuticals, Inc. Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
MX2010000465A (es) * 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
CN101855228B (zh) * 2007-09-11 2012-10-24 杏林制药株式会社 作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
US8476261B2 (en) 2007-09-12 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
AU2008324609B2 (en) * 2007-11-07 2015-04-23 Wai Lun Ho Tunable vibration absorbing device
CA2706465A1 (fr) 2007-11-21 2009-05-28 Pharmaxis Ltd. Inhibiteurs de ssao/vap-1 de type haloallylamines et leurs utilisations
WO2009111611A2 (fr) * 2008-03-05 2009-09-11 Proteotech Inc. Composés, compositions et méthodes pour le traitement de l’accumulation du polypeptide amyloïde des îlots (iapp) dans le diabète
PL2947072T3 (pl) 2008-03-17 2017-05-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
US20120034155A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CN101658533A (zh) * 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送
US8048204B2 (en) 2008-09-23 2011-11-01 Rwdi Air Inc. Wall assembly
WO2010088450A2 (fr) 2009-01-30 2010-08-05 Celladon Corporation Procédés de traitement de maladies associées à la modulation de serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
PL2401267T3 (pl) * 2009-02-27 2014-06-30 Ambit Biosciences Corp Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
KR101748891B1 (ko) * 2009-03-11 2017-06-19 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-3 억제제로서의 7-시클로알킬아미노퀴놀론
JP2012520314A (ja) 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン 癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
US8146310B2 (en) * 2009-03-11 2012-04-03 Keene Building Products Co., Inc. Noise control flooring system
WO2010110686A1 (fr) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl et 1,3,5-triazinyl benzimidazoles et leur utilisation en thérapie anticancéreuse
AU2010229468A1 (en) 2009-03-27 2011-10-13 Vetdc, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
AR076363A1 (es) 2009-04-22 2011-06-08 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida
SG175748A1 (en) 2009-04-22 2011-12-29 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide ccr3 antagonists
PE20120810A1 (es) 2009-04-22 2012-07-08 Axikin Pharmaceuticals Inc Compuestos derivados de 5-ciano-2-(feniltio)bencensulfonamida como antagonistas de ccr3
WO2011003870A2 (fr) 2009-07-06 2011-01-13 Creabilis S.A. Corticostéroïdes mini-pegylés, compositions les comprenant et procédés pour les préparer et les utiliser
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
ES2655883T5 (es) 2009-07-08 2022-04-18 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Composiciones farmacéuticas que contienen tiosulfato de sodio
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
BR112012003661A2 (pt) 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
NL2003697C2 (nl) 2009-10-22 2011-04-26 Univ Twente Weg met geluid-diffractoren.
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
WO2011056764A1 (fr) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Imidazo[2,1-b][1,3]benzothiazoles enrichis en isotopes ou fluores
WO2011057214A2 (fr) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Composés de modulation de la gamma-sécrétase, procédés pour les identifier, et leurs utilisations
US8528286B2 (en) * 2009-11-10 2013-09-10 Keene Building Products Co., Inc. Sound control mat
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EP2515654A4 (fr) * 2009-12-23 2013-04-24 Map Pharmaceuticals Inc Analogues d'ergoline
WO2011094890A1 (fr) 2010-02-02 2011-08-11 Argusina Inc. Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
EP2542542B1 (fr) 2010-03-02 2015-04-22 Axikin Pharmaceuticals, Inc. Antagonistes de ccr3 à base d'arylsulfonamide enrichi en isotope
WO2011112689A2 (fr) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Sels d'indazolylpyrrolotriazine
WO2011116161A2 (fr) 2010-03-17 2011-09-22 Axikin Pharmaceuticals Inc. Antagonistes du ccr3 de type arylsulfonamide
WO2011150201A2 (fr) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Composés azolylamide et leurs procédés d'utilisation
WO2011150198A1 (fr) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Composés azolyle urée et leurs procédés d'utilisation
WO2011153197A1 (fr) 2010-06-01 2011-12-08 Biotheryx, Inc. Dérivés d'hydroxypyridone, compositions pharmaceutiques réalisées à partir de ces dérivés, et utilisations thérapeutiques correspondants pour traiter des maladies prolifératives
CA2801003A1 (fr) 2010-06-01 2011-12-08 Biotheryx, Inc. Methodes permettant de traiter des tumeurs malignes hematologiques au moyen de 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
NZ604018A (en) 2010-06-07 2015-02-27 Novomedix Llc Furanyl compounds and the use thereof
MX347927B (es) 2010-07-19 2017-05-19 Summa Health System Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
US20140200270A1 (en) 2013-01-11 2014-07-17 Summa Health System Vitamins c and k for treating polycystic diseases
WO2012030914A1 (fr) 2010-09-01 2012-03-08 Ambit Boisciences Corporation Dérivés de 4-azolylaminoquinazoline et leurs méthodes d'utilisation
US20130303533A1 (en) 2010-09-01 2013-11-14 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012030910A1 (fr) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Dérivés de 2-cycloquinazoline et leurs méthodes d'utilisation
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
EP2611812A1 (fr) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Composés thiénopyridines et thiénopyrimidines et leurs procédés d'utilisation
US8912324B2 (en) 2010-09-01 2014-12-16 Ambit Biosciences Corporation Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
EP2611792B1 (fr) 2010-09-01 2017-02-01 Ambit Biosciences Corporation Sels hydrobromiques d'une pyrazolylaminoquinazoline
EP2611502A1 (fr) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Composés de modulation du récepteur a3 de l'adénosine et leurs méthodes d'utilisation
AU2011296024B2 (en) 2010-09-01 2015-05-28 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
WO2012030912A1 (fr) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Dérivés de 7-cyclylquinazoline et leurs méthodes d'utilisation
WO2012044641A1 (fr) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinylbenzimidazolsulfonamides et leur utilisation en thérapie anticancéreuse
US20120088769A1 (en) 2010-10-11 2012-04-12 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
US20120125711A1 (en) * 2010-11-24 2012-05-24 Stahr Richard E Sound absorbing panel and system
WO2012078649A1 (fr) 2010-12-06 2012-06-14 Follica, Inc. Procédés destinés à traiter la calvitie et à favoriser la croissance des cheveux
WO2012080050A1 (fr) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Formes solides d'un composé de phénoxybenzènesulfonyle
EP3763740A1 (fr) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anticorps anti-kit et leurs utilisations
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
AU2012236722A1 (en) 2011-03-28 2013-10-17 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20140088103A1 (en) 2011-03-28 2014-03-27 Mei Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
EP2691384B1 (fr) 2011-03-28 2016-10-26 MEI Pharma, Inc. (aralkylamino- et heteroaralkylamino)-pyrimidinyl- et 1,3,5-triazinyl-benzimidazoles substitues sur la position alpha, compositions pharmaceutiques les contenant et ces composes destines a etre utilises dans le traitement des maladies proliferatives
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2723735A4 (fr) 2011-06-23 2015-02-18 Map Pharmaceuticals Inc Nouveaux analogues de fluoro-ergoline
WO2013037482A1 (fr) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Agonistes du récepteur du farnésoïde x pour le traitement et la prévention du cancer
MY167575A (en) 2011-10-14 2018-09-20 Ambit Biosciences Corp Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
AU2012355982A1 (en) 2011-12-19 2014-07-10 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
US8946420B2 (en) 2011-12-21 2015-02-03 Map Pharmaceuticals, Inc. Neuromodulatory compounds
WO2013130600A1 (fr) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Formes solides comprenant de la pyrazolylaminoquinazoline optiquement active, compositions à base de celles-ci et leurs utilisations
TW201341367A (zh) 2012-03-16 2013-10-16 Axikin Pharmaceuticals Inc ３，５－二胺基吡唑激酶抑制劑
SI2844637T1 (en) 2012-05-02 2018-07-31 Boehringer Ingelheim International Gmbh Substituted 3-haloallylamine inhibitors of ssao and uses thereof
US9732038B2 (en) 2012-06-14 2017-08-15 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of STAT3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
CN104812775B (zh) 2012-07-25 2019-05-03 塞尔德克斯医疗公司 抗kit抗体及其用途
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
US9156799B2 (en) 2012-09-07 2015-10-13 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2014055647A1 (fr) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl et sulfonyl benzimidazolyl) pyrimidines et triazines, compositions pharmaceutiques les contenant, et leur utilisation pour traiter les maladies prolifératives
US20150272924A1 (en) 2012-11-08 2015-10-01 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
AU2013352106B2 (en) 2012-11-30 2018-04-26 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
CA2895829A1 (fr) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Nouveaux derives de methysergide
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
SG10201708143QA (en) 2013-06-06 2017-11-29 Pf Medicament Anti-c10orf54 antibodies and uses thereof
WO2015005774A1 (fr) * 2013-07-07 2015-01-15 4Silence B.V. Dispositif de diffraction pour diffracter un son
CN105683182A (zh) 2013-08-30 2016-06-15 埃姆比特生物科学公司 联芳基乙酰胺化合物及其使用方法
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (fr) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
EP3450571B1 (fr) 2014-02-24 2023-04-05 Celgene Corporation Procédés d'utilisation d'un activateur du céréblon pour l'expansion de cellules neurales et le traitement de troubles du système nerveux central
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
TWI705967B (zh) 2014-03-20 2020-10-01 美商卡佩拉醫療公司 苯并咪唑衍生物及其醫藥組合物及使用方法
CA3175724C (fr) 2014-03-20 2024-01-09 Capella Therapeutics, Inc. Derives de benzimidazole, compositions pharmaceutiques et methodes d'utilisation
EP3142649B1 (fr) 2014-05-12 2019-07-24 Conatus Pharmaceuticals, Inc. Traitement des complications de maladies hépatiques chroniques avec l'inhibiteur de caspase emricasan
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
JP2017526713A (ja) 2014-09-12 2017-09-14 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック併用療法
EP3209658A1 (fr) 2014-10-24 2017-08-30 Biogen MA Inc. Dérivés de diterpénoïdes et leurs procédés d'utilisation
EP3789039A1 (fr) 2014-12-22 2021-03-10 The Rockefeller University Anticorps agonistes anti-mertk et leurs utilisations
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kináz inhibitorok
CN113149982A (zh) 2015-01-20 2021-07-23 Xoc制药股份有限公司 麦角灵化合物及其用途
CN107428749B (zh) 2015-01-28 2020-07-24 上海复旦张江生物医药股份有限公司 取代的咪唑并[1,2-α]吡啶-2-基胺化合物及其药物组合物和使用方法
KR102740384B1 (ko) 2015-03-03 2024-12-06 키맵 리미티드 항체, 용도 및 방법
CA2986765A1 (fr) 2015-05-29 2016-12-08 Agenus Inc. Anticorps anti-ctla-4 et methodes d'utilisation de ceux-ci
WO2016210180A2 (fr) 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Inhibiteurs de vmat2 pour le traitement de maladies ou troubles neurologiques
EP3344656A1 (fr) 2015-09-01 2018-07-11 Agenus Inc. Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
IL284874B2 (en) 2015-10-30 2023-10-01 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
WO2017079566A1 (fr) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Inhibiteurs de caspase destinés à être utilisés dans le traitement du cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
EP4455145A3 (fr) 2015-12-02 2025-03-12 Astraea Therapeutics, LLC Composés de récepteur de la pipéridinyl nociceptine
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
EP3397251A1 (fr) 2015-12-31 2018-11-07 Conatus Pharmaceuticals, Inc. Méthodes d'utilisation d'inhibiteurs de caspase dans le traitement d'une hépatopathie
MX385964B (es) 2016-01-08 2025-03-18 Celgene Corp Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos.
EP3399978B1 (fr) 2016-01-08 2020-09-09 Celgene Corporation Composés antiprolifératifs, leurs compositions pharmaceutiques et leurs utilisations
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
US10064855B2 (en) 2016-03-08 2018-09-04 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
WO2017156183A1 (fr) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Dérivés de camptothécine et leurs utilisations
WO2017180589A1 (fr) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Dérivés de kétamine deutérés
EP4190357A1 (fr) 2016-05-13 2023-06-07 Institut Pasteur Inhibition de recepteurs nicotiniques beta-2 de l'acetylcholine pour traiter la pathologie de la maladie d'alzheimer
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
MX389710B (es) 2016-05-27 2025-03-20 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
DE102016111064A1 (de) * 2016-06-16 2017-12-21 Vossloh-Werke Gmbh Elastisches Element für einen Befestigungspunkt für eine Schiene für Schienenfahrzeuge und Befestigungspunkt
CN106087611B (zh) * 2016-06-20 2019-07-12 勾厚渝 轨道交通构件
EP3481864A1 (fr) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anticorps anti-apoc3 et leurs méthodes d'utilisation
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
MX390121B (es) 2016-09-19 2025-03-20 Mei Pharma Inc Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR102431830B1 (ko) 2016-11-07 2022-08-16 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
WO2018089692A1 (fr) 2016-11-09 2018-05-17 Phloronol, Inc. Dérivés d'eckol, procédés de synthèse et utilisations associées
WO2018089427A1 (fr) 2016-11-09 2018-05-17 Novomedix, Llc Sels de nitrite de 1,1-dimethylbiguanide, compositions pharmaceutiques et méthodes d'utilisation
WO2018102252A1 (fr) 2016-11-30 2018-06-07 North Carolina State University Procédés de fabrication de macrocycles bactériochlorines comprenant un noyau isocyclique annelé et des composés apparentés
JP7105774B2 (ja) 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド がん治療のための方法
TW202345829A (zh) 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
KR20230169457A (ko) 2017-01-27 2023-12-15 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
AU2018220515B2 (en) 2017-02-17 2022-06-30 DayLife LLC Universal antivenom
CN116730920A (zh) 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
WO2018164996A1 (fr) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Posologie pour la valbénazine
KR20190133198A (ko) 2017-03-27 2019-12-02 셀진 코포레이션 면역원성의 감소를 위한 방법 및 조성물
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
CA3059133A1 (fr) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anticorps anti-apoc3 et leurs methodes d'utilisation
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CA3067416A1 (fr) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. Utilisation d'anticorps anti-fam19a5 pour le traitement de cancers
CN111344011B (zh) 2017-06-27 2024-01-26 纽洛可科学有限公司 抗fam19a5抗体用于治疗纤维化的用途
JP7076059B2 (ja) 2017-06-27 2022-05-27 ニューラクル サイエンス カンパニー リミテッド 抗ｆａｍ１９ａ５抗体及びその用途
JP6904616B2 (ja) 2017-06-27 2021-07-21 ニューラクル サイエンス カンパニー リミテッド 緑内障治療のための配列相同性を有するファミリー、メンバーａ５抗体の用途
ES2953032T3 (es) 2017-09-01 2023-11-07 Univ East Carolina Métodos ex vivo para la activación de las células inmunológicas
RS66714B1 (sr) 2017-09-21 2025-05-30 Neurocrine Biosciences Inc Formulacija visoke doze valbenazina i sastavi, postupci i kompleti povezani sa njim
CN111263820B (zh) 2017-10-02 2024-07-02 纽洛可科学有限公司 抗序列相似家族19成员a5抗体用于治疗和诊断情绪障碍的用途
CA3076920A1 (fr) 2017-10-04 2019-04-11 The Regents Of The University Of California Oligosaccharides immunomodulateurs
MX2020003421A (es) 2017-10-10 2020-07-20 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3080103A1 (fr) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anticorps anti-apoc3 et leurs procedes d'utilisation
WO2019139871A1 (fr) 2018-01-10 2019-07-18 Cura Therapeutics Llc Compositions pharmaceutiques comprenant des acides dicarboxyliques et leurs applications thérapeutiques
AU2019207491A1 (en) 2018-01-10 2020-07-30 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
MA52137A (fr) 2018-03-23 2021-01-27 Eidos Therapeutics Inc Méthodes de traitement de l'amylose ttr à l'aide d'ag10
AU2019259798A1 (en) 2018-04-24 2020-11-12 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain
KR20240056644A (ko) 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
EP3806856A1 (fr) 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Composés inhibiteurs de vmat2, compositions et méthodes associées
CN108836091B (zh) * 2018-06-27 2020-12-04 贵州筑信达创科技有限公司 导轨
CN108533609B (zh) * 2018-06-27 2020-03-10 贵州筑信达创科技有限公司 导轨及滑动件的组合结构
EP3814327A1 (fr) 2018-06-29 2021-05-05 Histogen, Inc. Dérivés d'acide (s)-3-(2-(4-(benzyl)-3-oxopipérazin-1-yl)acétamido)-4-oxo-5-(2,3,5,6-tétrafluorophénoxy)pentanoïque et composés apparentés utilisés en tant qu'inhibiteurs de caspase pour le traitement de maladies cardiovasculaires
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
AU2019321583C1 (en) 2018-08-17 2025-11-27 Eidos Therapeutics, Inc. Formulations of AG10
AU2019352017A1 (en) 2018-10-03 2021-05-06 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
AU2019363368A1 (en) 2018-10-16 2021-05-13 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies
CN113365650A (zh) 2018-11-16 2021-09-07 新免疫技术有限公司 用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
WO2020118042A1 (fr) 2018-12-05 2020-06-11 Jacobs Wagner Christine Peptidoglycane de borrelia burgdorferi en tant qu'agent diagnostique et cible pour une intervention thérapeutique dans des pathologies associées à la maladie de lyme
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
EP3898609A1 (fr) 2018-12-19 2021-10-27 Shy Therapeutics LLC Composés interagissant avec la superfamille ras pour le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladie fibrotique
JP7239216B2 (ja) 2018-12-27 2023-03-14 ニューラクル サイエンス カンパニー リミテッド 粥状硬化症を治療するための抗ｆａｍ１９ａ５抗体の使用
CN113195533B (zh) 2019-01-02 2024-04-26 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体及其使用方法
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
ES2978570T3 (es) 2019-02-26 2024-09-16 Inspirna Inc Anticuerpos anti-MERTK de alta afinidad y sus usos
WO2020181165A1 (fr) 2019-03-07 2020-09-10 Conatus Pharmaceuticals Inc. Inhibiteurs de caspase et leurs procédés d'utilisation
CN114222802B (zh) 2019-05-20 2025-07-11 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法
JP7754724B2 (ja) 2019-05-20 2025-10-15 ニルバナ サイエンシーズ インク． 発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法
AU2020311404A1 (en) 2019-07-11 2022-03-03 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
AU2020310190A1 (en) 2019-07-11 2022-02-24 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
KR20220053007A (ko) 2019-08-30 2022-04-28 아게누스 인코포레이티드 항-cd96 항체 및 이의 사용 방법
JP7566889B2 (ja) 2019-09-16 2024-10-15 ダイス・アルファ・インコーポレイテッド Ｉｌ－１７ａモジュレーターおよびその使用
KR102337657B1 (ko) * 2019-11-06 2021-12-09 한국철도기술연구원 철도진동저감용 조립식 블록 및 이를 이용한 블록 구조물
US20230057939A1 (en) 2020-01-13 2023-02-23 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
CN113136745B (zh) * 2020-01-17 2024-10-25 洛阳双瑞橡塑科技有限公司 一种轨道道床吸音减振装置
WO2021151001A1 (fr) 2020-01-22 2021-07-29 Outpace Bio, Inc. Polypeptides chimères
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
US12006643B2 (en) * 2020-05-27 2024-06-11 Mute Wall Systems, Inc. Sound dampening barrier wall
EP4157271A1 (fr) 2020-05-29 2023-04-05 Boulder Bioscience LLC Procédés pour une thrombectomie endovasculaire améliorée à l'aide de 3,3'-diindolylméthane
WO2021257828A1 (fr) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Thiénopyrimidines qui interagissent avec la superfamille ras pour le traitement de cancers, de maladies inflammatoires, de rasopathies et d'une maladie fibreuse
EP4149471A4 (fr) 2020-06-30 2024-07-10 Prosetta Biosciences, Inc. Dérivés d'isoquinoléine, leurs procédés de synthèse et leurs utilisations
WO2022061348A1 (fr) 2020-09-16 2022-03-24 Biotheryx, Inc. Agents de dégradation de protéine sos1, compositions pharmaceutiques de ceux-ci, et leurs applications thérapeutiques
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
US20240101629A1 (en) 2020-11-02 2024-03-28 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
CN116615236A (zh) 2020-11-05 2023-08-18 新免疫技术有限公司 用il-7蛋白和核苷酸疫苗的组合治疗肿瘤的方法
CN112712784B (zh) * 2020-11-30 2024-12-31 南京华秦光声科技有限责任公司 一种低频宽带平板吸声结构
AU2021402911A1 (en) 2020-12-14 2023-07-06 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
US20240124483A1 (en) 2021-01-27 2024-04-18 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
US20240309015A1 (en) 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
IL305752A (en) 2021-03-10 2023-11-01 Dice Molecules Sv Inc INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
WO2022226166A1 (fr) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Imidazolidinediones et imidazolidinones spirocycliques pour le traitement d'une amylose à chaîne légère
EP4347568A1 (fr) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Hétéroaryl-diamides activateurs d'ire1/xbp1s
WO2022251644A1 (fr) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Cellules immunitaires déficientes en nr4a3 et leurs utilisations
JP2024520676A (ja) 2021-06-02 2024-05-24 ライエル・イミュノファーマ・インコーポレイテッド Ｎｒ４ａ３欠損免疫細胞及びその使用
CA3218481A1 (fr) 2021-06-14 2022-12-22 argenx BV Anticorps anti-il-9 et leurs procedes d'utilisation
WO2022266249A1 (fr) 2021-06-16 2022-12-22 Biotheryx, Inc. Agents de dégradation de protéine kras, compositions pharmaceutiques associées, et leurs applications thérapeutiques
JP2024522768A (ja) 2021-06-16 2024-06-21 バイオセリックス， インコーポレイテッド Ｓｏｓ１タンパク質分解剤、その医薬組成物及びそれらの治療的応用
US20240277857A1 (en) 2021-09-29 2024-08-22 Nbios, Inc. Coiled-coil fusion protein
AU2022368836A1 (en) 2021-10-22 2024-05-02 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
EP4456907A1 (fr) 2021-12-30 2024-11-06 NeoImmuneTech, Inc. Procédé de traitement d'une tumeur avec une combinaison d'une protéine il-7 et d'un antagoniste du vegf
WO2023129577A1 (fr) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Promédicaments à base de thiol cyclique
JP2025501308A (ja) 2022-01-03 2025-01-17 ライラック セラピューティクス， インク． 非環式チオールプロドラッグ
WO2023157989A1 (fr) 2022-02-17 2023-08-24 주식회사 노벨티노빌리티 Conjugué anticorps-médicament
JP2025507621A (ja) 2022-03-02 2025-03-21 ミトパワー， インク． ニコチン酸及びリボースから誘導体化した新規プロドラッグ
WO2023192904A1 (fr) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Oligonucléotides de saut d'exon de dystrophine
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
AR129053A1 (es) 2022-04-14 2024-07-10 Bristol Myers Squibb Co Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos
AU2023265665A1 (en) 2022-05-05 2024-10-10 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
IL316794A (en) 2022-05-10 2025-01-01 Biotheryx Inc CDK protease inhibitors, pharmaceuticals and therapeutic applications
KR20250027283A (ko) 2022-05-19 2025-02-25 라이엘 이뮤노파마, 인크. nr4a3을 표적하는 폴리뉴클레오타이드 및 이의 용도
JP2025531869A (ja) 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
EP4593826A1 (fr) 2022-09-30 2025-08-06 Boulder Bioscience LLC Compositions comprenant du 3,3'-diindolylméthane pour traiter une blessure fermée à la tête non hémorragique
JP2025537484A (ja) 2022-10-21 2025-11-18 ダイアゴナル・セラピューティクス・インコーポレイテッド Ｉｌ－１８受容体に対するヘテロマーアゴニスト抗体
WO2024092040A1 (fr) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Composés hétéroaryle bicycliques contenant un spirocycle
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
EP4608838A1 (fr) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Composés de pyridone contenant un spirocycle
KR20250089492A (ko) 2022-11-07 2025-06-18 네오이뮨텍, 인코퍼레이티드 비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
WO2024118810A1 (fr) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Activateurs de ire1/xbp1 diamide de pyrazole cyclique
EP4626864A1 (fr) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Diamides hétéroaryles linéaires comme activateurs d'ire1/xbp1s
KR102870410B1 (ko) * 2022-12-09 2025-10-16 한국전자기술연구원 방음재 및 소음 제어 시스템
WO2024194685A2 (fr) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anticorps anti-phosphocholine et leurs procédés d'utilisation
AU2024240129A1 (en) 2023-03-17 2025-10-09 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
EP4688147A1 (fr) 2023-04-07 2026-02-11 Diagonal Therapeutics Inc. Anticorps agonistes bispécifiques pour activer un récepteur de type 1 (alk1)
AU2024254039A1 (en) 2023-04-07 2025-10-02 Diagonal Therapeutics Inc. Hinge-modified bispecific antibodies
WO2024226471A2 (fr) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions et méthodes de traitement de troubles liés à stxbp1
TW202448485A (zh) 2023-05-05 2024-12-16 美商拜奧馬林製藥公司 肌萎縮蛋白外顯子跳躍寡核苷酸
EP4709725A1 (fr) 2023-05-09 2026-03-18 Progentos Therapeutics, Inc. Composés hétérocycliques et leurs utilisations
AU2024276812A1 (en) 2023-05-19 2025-11-06 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to il12 receptor
KR20260033048A (ko) 2023-07-03 2026-03-10 네오이뮨텍, 인코퍼레이티드 이종이합체 fc 분자 및 이의 용도
WO2025046298A2 (fr) 2023-09-01 2025-03-06 iTeos Belgium SA Anticorps anti-trem2 et procédés d'utilisation
AU2024344247A1 (en) 2023-09-19 2026-05-07 Kancure Pte. Ltd. Survivin-targeted compounds
IL327069A (en) 2023-09-27 2026-05-01 Isosterix Inc Mist inhibitors
WO2025085416A1 (fr) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Composés gspt1 et procédés d'utilisation des composés
AU2024366926A1 (en) 2023-10-23 2026-03-12 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025133707A1 (fr) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anticorps anti-tdp-43 et leurs utilisations
WO2025147691A1 (fr) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions et procédés de dégradation de protéine de translocation nucléaire de récepteur d'hydrocarbure aryle
WO2025179161A1 (fr) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Composés de dégradation de protéines
WO2025201633A1 (fr) 2024-03-26 2025-10-02 Chen Gefei Agent pour réduire la formation d'amyloïdes
WO2025255341A1 (fr) 2024-06-05 2025-12-11 Protego Biopharma, Inc. Activateurs de tétrahydrofuranyle ire1/xbp1s
WO2026080748A2 (fr) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Anticorps du récepteur de la protéine morphogénétique osseuse de type 2 (bmprii)
WO2026080752A2 (fr) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Nouvel anticorps dirigé contre la kinase 1 de type récepteur de l'activine (alk1)
WO2026080757A2 (fr) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Anticorps du récepteur de l'activine de type ii a/b (actriia/b)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991848A (en) * 1974-08-16 1976-11-16 Frigitemp Acoustical board
US4142468A (en) * 1976-04-20 1979-03-06 Charles Birnstiel Elevated rail transit guideway with noise attenuators
US4093120A (en) 1977-01-24 1978-06-06 Park Rubber Company Railroad crossing structure
DE7711191U1 (de) 1977-04-07 1978-09-28 Straetner Geb. Buss, Anita, 4300 Essen Fahrbahnplatte fuer schienengleiche bahnuebergaenge
DE7719283U1 (de) 1977-06-20 1977-10-27 Gummiwerk Kraiburg Gmbh & Co, 8264 Waldkraiburg Platte fuer schienengleiche bahnuebergaenge
DE3602313A1 (de) * 1986-01-27 1987-07-30 Clouth Gummiwerke Ag Schallabsorbierender laermschutz insbesondere fuer schotterlose gleise
DE3827547C2 (de) * 1988-08-13 2000-09-21 Zueblin Ag Schallabsorptionskonstruktion für schotterlose Eisenbahnoberbauten
US4960184A (en) * 1989-11-09 1990-10-02 Bruce Woodward Sound absorbing structure
DE4243102A1 (en) * 1991-12-20 1993-07-01 Bold Karl Gmbh & Co Noise protection and sight wall with carrier girder construction
DE69405881T2 (de) * 1994-02-11 1998-03-19 Autostrade Concess Const Schalldämpfender strassenbelag und verfahren zu dessen herstellung
DE4414566C2 (de) * 1994-04-27 1997-11-20 Freudenberg Carl Fa Luftschalldämpfer
DE4417402A1 (de) 1994-05-18 1995-11-23 Gruenzweig & Hartmann Montage Schallschutzeinrichtung zur Schalldämpfung und -dämmung an Gleiskörpern
NL194553C (nl) * 1994-06-06 2002-07-02 Veldhoen Raalte B V Inrichting voor de geluidsisolatie van een spoorbaan.
DE29515935U1 (de) * 1995-10-07 1995-11-30 Deutsche Asphalt GmbH, 63263 Neu-Isenburg Schallabsorber für einen schotterlosen Eisenbahnoberbau
IT1293307B1 (it) * 1997-07-09 1999-02-16 Dieselbox Sa Barriera antirumore a pannelli trasparenti,dotata di caratteristiche fonoisolanti e fonoassorbenti

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9745592A1 *

Also Published As

Publication number Publication date
JP3822641B2 (ja) 2006-09-20
NO316078B1 (no) 2003-12-08
ES2186891T3 (es) 2003-05-16
WO1997045592A1 (fr) 1997-12-04
CA2255946A1 (fr) 1997-12-04
AU738889B2 (en) 2001-09-27
US6253872B1 (en) 2001-07-03
HUP9903612A2 (hu) 2000-02-28
HUP9903612A3 (en) 2001-08-28
NO985600L (no) 1998-11-30
CA2255946C (fr) 2006-03-14
CN100424268C (zh) 2008-10-08
HU221872B1 (hu) 2003-02-28
TW345603B (en) 1998-11-21
DK0901536T3 (da) 2003-04-07
CN1219989A (zh) 1999-06-16
AU2880197A (en) 1998-01-05
DE59708955D1 (de) 2003-01-23
JP2000510921A (ja) 2000-08-22
EP0901536B1 (fr) 2002-12-11
NO985600D0 (no) 1998-11-30
ATE229595T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
EP0901536B1 (fr) Dispositif d'insonorisation pour voies ferrees
EP0904461B1 (fr) Recouvrement de niveau avec des rails, pour voies ferrees
WO2013075159A1 (fr) Dispositif anti-bruit
EP0214524B1 (fr) Moellon ou pavé en béton ou en matériau similaire
DE19705531C2 (de) Vorrichtung zur Überbrückung von Dehnfugen
EP0149697A1 (fr) Couvre-joint pour joints de dilatation dans des chaussées, en particulier dans des tabliers de pont
DE4430769C2 (de) Eisenbahnoberbau mit einem auf einer durchgehenden Tragplatte aus Stahlbeton aufgelagerten Gleisrost
DE3134473A1 (de) Schotterloser oberbau fuer schienenbahnen
DE102007037339A1 (de) Gabionenkorb mit lärmdämmender, monolithischer Schicht aus Beton
DE3827547C2 (de) Schallabsorptionskonstruktion für schotterlose Eisenbahnoberbauten
DE202011052057U1 (de) Lärmschutzvorrichtung
DE19514458A1 (de) Schallabsorbierendes Wandelement
DE29515935U1 (de) Schallabsorber für einen schotterlosen Eisenbahnoberbau
DE3544481A1 (de) Schallschutzwand und dafuer geeignetes wandelement
EP2817456B1 (fr) Dispositif anti-bruit
AT403809B (de) Schallschutzeinrichtung für gleise
EP1721045B1 (fr) Garnissage pour voie ferree reduisant les nuisances sonores
DE8717982U1 (de) Schallabsorbierendes Bauelement
DE19540357C1 (de) Eisenbahnbrücke und Kulisse zur Schalldämpfung an dieser
DE19635788A1 (de) Schalldämpfungselement für Schienentrassen mit fester Fahrbahn
EP1136622B1 (fr) Recouvrement de voie ferrée
EP0166719A2 (fr) Joint d'étanchéité profilé
AT512391B1 (de) Lärmschutzvorrichtung
DE2856367A1 (de) Plattenbelag fuer daecher sowie tragelemente fuer diese
DE2607538A1 (de) Verbundformsteinelement

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT CH DE DK ES FI FR GB IT LI LU PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 981130

17Q First examination report despatched

Effective date: 20000830

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT CH DE DK ES FI FR GB IT LI LU PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 19981130

REF Corresponds to:

Ref document number: 229595

Country of ref document: AT

Date of ref document: 20021215

Kind code of ref document: T

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 59708955

Country of ref document: DE

Date of ref document: 20030123

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20030329

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2186891

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20030912

REG Reference to a national code

Ref country code: SI

Ref legal event code: IF

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: GMUNDNER FERTIGTEILE GESELLSCHAFT M.B.H. & CO. KG

Free format text: GMUNDNER FERTIGTEILE GESELLSCHAFT M.B.H. & CO. KG.#KUFERZEILE 30-32#A-4810 GMUNDEN (AT) -TRANSFER TO- GMUNDNER FERTIGTEILE GESELLSCHAFT M.B.H. & CO. KG.#KUFERZEILE 30-32#A-4810 GMUNDEN (AT)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20120529

Year of fee payment: 16

Ref country code: DK

Payment date: 20120522

Year of fee payment: 16

Ref country code: LU

Payment date: 20120530

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20120529

Year of fee payment: 16

Ref country code: GB

Payment date: 20120425

Year of fee payment: 16

Ref country code: SE

Payment date: 20120518

Year of fee payment: 16

Ref country code: FI

Payment date: 20120523

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20120516

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20120730

Year of fee payment: 16

Ref country code: ES

Payment date: 20120504

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20120427

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20120525

Year of fee payment: 16

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20131125

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 229595

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130531

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20130523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130524

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131125

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131203

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20130531

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 59708955

Country of ref document: DE

Effective date: 20131203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130523

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130523

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140131

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20140225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130523

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20140610

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130523